T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy.

Altaf M., Nel C., Tipoe T., Edgar J., Zacharopoulou P., Srai D., Knight C., Lee M., Cherrill L-R., Falaschetti E., Ogbe A., Fletcher S., Box H., Elliott T., Kinloch S., Fox J., Clarke A., Pett S., Collins S., Balachandran M., Topping K., Terry L., Seaton K., Tomaras G., Uriel A., Orkin C., Ring K., Whitlock G., Boffito M., Sutherland R., Søgaard OS., Gunst JD., Brown H., Robinson N., Lindegard G., Goulder P., Taylor G., Caskey M., Nussenzweig M., Fidler S., Frater J., RIO Study Team .

DOI

10.64898/2026.02.02.26345374

Type

Preprint

Publication Date

2026-02-03T00:00:00+00:00

Keywords

HIV, T cells, broadly neutralising antibodies (bNABs), immunity, viral control

Permalink More information Close